TABNAK, Jun. 28 -An Iranian knowledge-based cell therapy product developed from umbilical cord–derived stem cells has entered clinical practice after receiving authorization from the country's Food and Drug Administration (FDA) for the treatment of osteoarthritis, marking another step in the expansion of regenerative medicine technologies in Iran.
News ID: 7529 Publish Date : 2026/06/28